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Abstract 
 
Introduction: Although growth advantage of certain clones would ultimately translate into 
a clinically visible disease progression, radiological imaging does not reflect clonal 
evolution at the molecular level. Circulating tumor DNA (ctDNA), validated as a tool for 
mutation detection in lung cancer, reflects dynamic molecular changes.  
Methods: We performed capture-based ultra-deep sequencing on longitudinal plasma 
samples utilizing a panel consisting of 168 non-small cell lung cancer (NSCLC)-related 
genes on 949 advanced NSCLC patients with drive mutations to monitor treatment 
responses and disease progression. Detailed survival analyses regarding the correlations 
between ctDNA and progression-free survival (PFS)/overall survival (OS) were performed 
on 248 patients undergoing heterogeneous treatments with a minimum of 2 ctDNA tests.  
Results:  This study revealed that higher ctDNA abundance (p=0.012) and mutation count 
(p=8.5x10-4) at baseline are associated with inferior OS. The association between ctDNA 
and PFS/OS was performed in a sub-cohort consisting of 248 patients with a minimum of 
2 evaluations beyond baseline. We revealed that patients with ctDNA clearance, not just 
driver mutation clearance, at any point during the course of treatment are associated with 
a longer PFS (p=2.2x10-16 HR=0.28) and OS (p=4.5x10-6 HR=0.19) regardless of the type 
of treatment commenced and the evaluation schedule.  
Conclusion: This prospective real-world study demonstrates that ctDNA clearance during 
treatment can serve as a predictive and a prognostic marker across a wide spectrum of 
treatment regimens.  
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Introduction   
 
The treatment of patients with advanced NSCLC has been revolutionized with the 
development of therapies directed at specific genetic alterations. The characterization of 
NSCLC into subtypes based on their genetic alterations has significantly improved the 
therapeutic efficacies of targeted therapies and disease outcomes in a subgroup of patients 
1-4. However, their efficacies are compromised by the development of resistance 
mechanisms, which inevitably arise in all patients with a median PFS ranging from a few 
months to a year due to clonal evolution 5-7. Currently, the response assessment primarily 
relies on imaging modalities, which do not reflect clonal evolution at the molecular level8. 
Therefore, there is an urgent need to develop improved modalities for monitoring clonal 
evolution. 
The genomic profile of ctDNA, predominantly released by apoptosis and necrosis 
of cancer cells, has been shown to closely match those of tumor samples 9,10. It has been 
validated as surrogate material for mutation detection in NSCLC11-13. For instance, plasma 
and tissue-based genotyping for EGFR T790M yielded equivalent clinical outcomes of 
Osimertinib, supporting plasma genotyping as an alternative diagnostic option14.  Much 
effort has been invested in exploring the potential of ctDNA in monitoring responses and 
assessing the emergence of drug resistance15-17. Among patients undergoing epidermal 
growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) treatment, a reduction in the 
allelic fraction (AF) of EGFR mutation reflects sensitivity to such inhibitors 18.  In addition, 
ctDNA has been instrumental in revealing novel resistance mechanisms, such as acquired 
EGFR C797S to osimertinib5, MET Y1248H and D1246N to c-Met inhibitors etc 19.  
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Patients harboring the same mutation exhibit marked differences in treatment 
responses 2. Circulating tumor DNA has been proposed to serve as noninvasive real-time 
biomarker to provide prognostic and predictive information in treatment monitoring 20-22. 
The prognostic value of ctDNA has been well-established in detecting minimal residual 
disease following surgery or treatment with curative intent and is being explored in 
treatment responses of advanced patients 23-26. A recent study has shown that the presence 
of ctDNA at diagnosis and the detection of residual ctDNA at first evaluation were 
associated with poor prognosis21. More work is needed to comprehensively examine its 
prognostic and predictive values in cohorts consisting of diverse treatment history.     
In this prospective real-world study, we performed capture-based ultra-deep 
targeted sequencing on longitudinal plasma samples to investigate the potential of ctDNA 
analysis at various treatment milestones in predicting clinical outcomes. We explored the 
genomic landscape of 1,336 Chinese patients with advanced NSCLC and focused on 248 
of them with a minimum of 2 monitoring points to interrogate the predictive and prognostic 
value of ctDNA as well as to investigate the dynamics of ctDNA upon pharmacological 
intervention by using a panel consisting of 168 NSCLC-related genes, covering 170KB of 
human genome.  
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Materials and Methods  
Patient selection  
From September 2015 to October 2016, advanced NSCLC (stage IIIB to IV) patients 
with specified mutations in at least one of the following genes EGFR, ALK, ROS 1, RET, 
KRAS, PIK3CA, ERBB2, MET, and BRAF were enrolled. Their longitudinal plasma 
samples were collected at baseline and various points throughout the treatment at multiple 
participating insititutes. Detailed inclusion criteria were listed in supplemental methods. 
This study was approved by a central ethic committee at Nanjing General Hospital of 
Nanjing Command (2016NZKY-003-02). All other centers were covered by this protocol 
except for First Affiliated Hospital of Guangzhou Medical University (IRB2016-26) and 
Tianjin Medical School Affiliated General Hospital (IRB2016-050-01). All patients gave 
informed consent to participate in the study and gave permission for the use of their 
peripheral blood. 
NGS library preparation and Capture-based targeted DNA sequencing 
Fragments of size 200–400bp were selected by AMPure beads (Agencourt AMPure 
XP Kit), followed by hybridization with capture probe baits, hybrid selection with 
magnetic beads and PCR amplification. Indexed samples were sequenced on Nextseq500 
sequencer (Illumina, Inc., USA) with pair-end reads. An average depth of 11,816x was 
reached.  
Statistical Analysis  
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All statistical tests were conducted in R (version 3.3.1), and all were 2-sided tests 
unless otherwise specified. For patient characteristics, the differences in distribution of 
continuous and categorical variables across groups were assessed using Wilcoxon and 
Fisher exact tests, respectively.  Survival tests were conducted using log-rank tests or Cox 
regression models when a co-variant was included. 
 
  
  
9 
 
Results  
Patient demographics and study design  
Within the screened population, 949 harbored driver mutation; 245 had no mutation 
detected and the remaining 142 patients had non-driver mutation. Approximately, 16% 
patients were treatment-naïve (207/1,336); 71% (949/1,336) were previously treated and 
the remaining 13.5% (181/1,336) had no treatment history information available. Thirty-
one percent of patients (410/1,336) had 1 line of previous treatment; 18.2% (244/1,336) 
had 2 lines; 11.1% (149/1,336) had 3 lines and the remaining 10.9% (146/1,336) had more 
than 3 lines of treatment (Figure 1A). The median follow-up time for patients enrolled in 
our study was 322 days. The median interval for ctDNA analysis was 95 days. Figure 1B 
depicts detailed treatment history (outer ring) and treatment information during our study 
(inner ring). Among the 949 patients harbored driver mutations at baseline, 376 patients 
received matched targeted therapy (MTT) according to sequencing results. A zoom-in view 
of their treatment prior to and during our study was shown in Supplemental Figure 1. 
Detailed survival analysis was performed on 248 patients (longitudinal cohort) with 2 or 
more evaluation time points beyond baseline. A total of 280 patients had 2 or more follow-
up tests and 32 of them were excluded due to various reasons. The selection of patients 
enrolled in the follow-up cohort was depicted in Fiugre1A.  
We first compared and contrasted baseline clinical parameters, including gender, 
age, smoking history, histology, stage, treatment history and metastatic sites between the 
longitudinal and the screened cohort. Our data demonstrated that the two cohorts were 
similar in most of parameters, except for gender and the percentage patients with bone 
metastasis (Supplemental Table 1). The longitudinal cohort had a female predominance, 
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had more people with bone metastasis and EGFR mutations. Since the presence of driver 
mutations is one of our inclusion criteria and EGFR is the most frequently occurred driver 
mutation in NSCLC, approximately 50% of patients harbored EGFR mutations, which are 
associated with a female predominance.  However, such differences do not skew analyses 
performed in this study.  
Landscape of baseline mutation  
We performed capture-based ultra deep targeted sequencing on all baseline plasma 
samples using a panel consisting of 168 genes, spanning 170KB of human genome. The 
design and validation of this panel has been described by Mao et al 9. It achieved 95% and 
87% by-variant sensitivity in identifying mutations from matched tissue and plasma 
samples, respectively, excluding copy number variations (CNVs) 9. DNA obtained from 
white blood cells (WBCs) was used as a reference to filter out germline mutations. Overall, 
an average of 11,816x sequencing depth was achieved.  
At baseline, we identified 3,503 aberrations spanning 132 genes, including 2,204 
single-nucleotide variants (SNVs), 693 insertions or deletions (Indels), 412 copy-number 
amplifications (CNAs), 80 copy number deletions, and 114 translocations. Approximately, 
18% of patients (245/1,336) had no mutations detected from this panel. EGFR was the 
most frequently mutated gene, followed by TP53, occurring in 55% and 41% of patients, 
respectively. Among all genetic aberrations identified, well-established NSCLC driver 
mutations, including EGFR, KRAS, BRAF, ERBB2, ALK, RET and ROS1, comprised 46.9% 
of all variants identified. The overview of the mutation spectrum is shown in Figure 2A.  
Next, we investigated the clinical relevance of baseline max allelic fraction (max 
AF) and total cell-free DNA (cfDNA). MaxAF was defined as the maximum allelic fraction 
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among all somatic mutations identified in a plasma sample. Higher maxAF and cfDNA 
were associated with more advanced M stage, a higher likelihood of bone/liver metastasis 
and having more organs with lesions (Figure 2B). Interestingly, maxAF showed a more 
significant correlation than the amount of cfDNA with all clinical features tested.  
Overall survival is correlated with baseline ctDNA abundance and mutation load 
We performed detailed analysis on the longitudinal cohort to assess the predictive 
and prognostic potential of ctDNA. First, we investigated the correlation between overall 
survival (OS) and baseline parameters, including ctDNA abundance and mutation load. 
Previous studies interrogating the correlation between mutation load at baseline and overall 
survival have given inconsistent results 27,28.  Our data revealed an inverse correlation 
between baseline ctDNA amount imputed by the product of maxAF and total amount of 
cfDNA and OS (p=0.012). The mutation count was also inversely correlated with OS 
independent of baseline ctDNA amount (P=8.5x10-4) (Figure 3A-B). Next, we derived a 
molecular signature for OS prediction using multi-variate stepwise regression, starting 
from 6 gens that were individually associated with OS: CDKN2A, EGFR, KEAP1, KRAS, 
MET and POM121L12. The final molecular signature consists of KEAP1, KRAS and MET. 
Patients with no mutations in these genes are associated with a longer OS (p<0.0001) 
(Figure 3C).  
ctDNA clearance predicts longer progression-free survival and overall survival 
 
In clinical settings, treatment response is typically monitored on a regular interval 
by radiological imaging, which does not reflect clonal evolution.  We interrogated the 
potential of utilizing ctDNA as a surrogate for monitoring treatment response using our 
longitudinal cohort, which had at least 2 ctDNA tests. After a median follow-up of 157 
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days, 166 (66.9%) patients reached disease progression. During the course of treatment, 
123 patients, treated with either MTT or chemotherapy, had a minimum of one time of 
ctDNA clearance, occurring from 1 month to 15 months after the commencement of 
treatment, with a median PFS of 8.6 months.  Fifty patients achieved partial response (PR), 
67 achieved stable disease (SD) and 3 achieved progressive disease (PD) as their best 
response, resulting in an overall response rate (ORR) of 41.7% and a disease control rate 
(DCR) of 97.5%. Up to June 25, 2017, median overall survival (OS) for this group has not 
been reached.  In contrast, 125 patients with consistent detectable ctDNA throughout the 
course of treatment had a median PFS of 4.1 months and a median OS of 16.7 months. 
Among them, 14 achieved PR, 64 achieved SD and 38 achieved PD as their best response, 
resulting in an ORR of 12.1% and a DCR of 67.2%. Taken together, our data revealed that 
patients with a minimum of one time ctDNA clearance are associated with a longer PFS 
(p=2.2x10-16; HR=0.28) and OS (p=4.5x10-6 HR=0.19) independent of baseline ctDNA 
amount, regardless of the type of treatment commenced and the time of evaluation (Figure 
4A). The baseline clinical parameters including gender, smoking history, stage, treatment 
history etc of patients with minimum of one time ctDNA clearance and patients with 
consistent detectable ctDNA were comparable, except for gender (Supplemental Table 2).  
Furthermore, patients with a minimum of one time ctDNA clearance had a better ORR 
(p=3.9x10-7) and DCR (p=1.4x10-10) comparing to patients had detectable ctDNA 
throughout the course of treatment. The same trend was observed for patients treated with 
MTT (Figure 4B) but not for patients treated with chemotherapy (Supplemental Figure 2). 
Circulating tumor DNA clearance can predict PFS (p=0.022) but not OS (p=0.22) in 
chemotherapy-treated patients after controlling for baseline ctDNA amount. Collectively, 
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our data demonstrate ctDNA can serve as a valuable real-time biomarker to monitor 
therapeutic response and its clearance at any point of treatment can predict treatment 
benefits. This phenomenon reflects clonal response, thus demonstrating the biological 
nature underlying the clinical response.  
Previous studies have reported a reduction in ctDNA amount during treatment is 
associated with favorable therapeutic efficacy 21. Next, we evaluated whether ctDNA 
clearance or certain degree of ctDNA reduction reflected by maxAF would better correlate 
with treatment efficacies. To derive a binary classifier which can differentiate the 
population based on treatment efficacy, we conducted a receiving operating curve (ROC) 
analysis of changes in maxAF during the course of treatment and identified a reduction in 
maxAF to zero as the optimal cutoff, achieving an area under curve (AUC) of 75% (Figure 
4C). Change in maxAF was defined as the ratio of smallest maxAF detected in follow-up 
evaluations and baseline.  Thus, ctDNA clearance but not its reduction upon 
pharmacological interventions serves as a predictive marker. 
Next, we evaluated whether the clearance of driver mutation can provide equal 
predictive power as ctDNA clearance for PFS. We compared PFS among 3 groups of 
patients: with all mutation clearance, only driver mutation clearance and with the presence 
of driver mutations. No difference in PFS was observed for patients with only driver 
mutation clearance and patients with driver mutation, suggesting only monitoring 
corresponding driver mutation can not predict PFS (Figure 4D).  
Early detection of disease progression   
                We investigated whether a re-elevation in ctDNA can be detected prior to 
radiological assessment of disease progression. Due to the heterogeneity of treatments in 
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our cohort, we focused on patients undergoing osimertinib treatment (n=74) to examine 
the potential of ctDNA in early detection of PD. Forty patients experienced radiological 
PD; among whom, 53.1% had at least one liquid biopsy prior to radiological assessment of 
PD.  A comparison of ctDNA level reflected by maxAF among baseline and all points prior 
to radiological assessment of PD was performed. Fifty-three percent of patients showed an 
elevation of ctDNA comparing to baseline reflected by either an increase in allelic fraction 
of any existing mutation or the emergence of new mutation prior to PD assessed by 
radiological modalities, with an average leading time of 64 days (Figure 5).  Collectively, 
our data demonstrate the ability of ctDNA in reflecting disease progression and can occur 
prior to radiological PD.  
  
15 
 
Discussion  
Therapeutic response is often assessed using radiological imaging, which does not 
capture clonal dynamics and evolutionary changes upon pharmacological interventions. 
Recent studies have demonstrated the potential of ctDNA as a tool for real-time tracking 
of molecular dynamics to predict treatment response based on residual disease 21,22. In this 
study, we evaluated the potential of ctDNA by performing capture-based ultra deep 
sequencing on longitudinal plasma samples obtained at various treatment milestones from 
248 advanced NSCLC patients. Our real world study, comprising both treatment-naïve and 
previously treated patients, demonstrates ctDNA can serve as a valuable real-time 
biomarker to monitor therapeutic response and its clearance at any point of treatment can 
predict treatment benefits. Circulating tumor DNA clearance is defined as no mutation 
detected from this panel with an average sequencing depth of 11,816x and 0.2% limit of 
detection. Patients with a minimum of one time ctDNA clearance during the course of 
treatment were associated with a statistically significant longer PFS and OS. In contrast, 
patients with detectable ctDNA throughout the course of treatment are associated with 
inferior treatment response and survival.  We cannot rule out the possibility that patients 
with ctDNA clearance had mutations with AFs below the limit of detection-0.2%.  
The prognostic value of ctDNA at first evaluation has been reported in a prospective 
study comprising only newly diagnosed patients undergoing first-line treatment 21. Our 
study, consisting of a heterogeneous population and diverse evaluation schedules, not only 
confirmed the finding from previous study, but also extended the power of ctDNA analysis 
in predicting treatment benefits to all patients regardless of treatment history and evaluation 
time. Furthermore, we demonstrated that ctDNA clearance can translate to clinical benefits 
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reflected by longer PFS and OS. Our study warrants further investigations to explore the 
value of ctDNA clearance as surrogate endpoint of efficacy and as a risk stratification factor, 
differentiating poor and favorable prognosis.  
Our study also revealed the potential of ctDNA in early detection of disease 
progression, preceding imaging modalities with a median lead time of 64 days. This finding 
echoes with previous studies across a range of different cancer types, including but not 
limited to breast cancer 29, colorectal cancer and NSCLC21,30.  However it is important to 
note this study was not designed to assess how much earlier ctDNA can detect disease 
progression than imaging modalities; in many patients, ctDNA analysis and CT scans were 
not performed in close time frame.  It is also noteworthy to point out that for heavily treated 
patients, earlier detection of PD can only offer limited survival benefits due to the 
exhaustion of treatment options, suggesting the value of early detection of PD at the 
molecular level in guiding treatment may be better reflected in first-line patients.  In most 
cases, ctDNA analysis was performed after the assessment of PD by imaging modalities. 
Therefore, further prospective studies are needed to confirm earlier detection of PD by 
ctDNA and to accurately define the lead time.  Prospective studies evaluating the clinical 
impact of early therapeutic switch based on ctDNA presence instead of imaging modalities 
are needed to fully validate our findings.   
The prognostic and predictive value of ctDNA concentration prior to treatment has 
always been a controversial issue with conflicting data reported. Most of studies have 
reported high ctDNA level at baseline is associated with unfavorable PFS and OS; in 
contrast, others have reported there is no clear correlation 21,31,32.  In this study, we also 
evaluated the prognostic value of baseline ctDNA amount in relation to OS and revealed 
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an inverse correlation.  The heterogeneity of our cohort, reflected by diverse treatment 
history, staging and tumor burden, may affect the analysis.  Furthermore, a recently 
published study has shown novel determinants of ctDNA detection in NSCLC, including 
the degree necrosis, lymph node involvement, lymphovascular invasion, pathological 
tumor size, Ki67 labelling indices and tumor histology33.  Therefore, large cohort studies 
controlling for such factors are needed to accurately define the prognostic and predictive 
value of baseline ctDNA. Furthermore, we also derived a molecular signature, which 
predicts OS. There are a few limitations associated with this study, including the 
heterogeneity of treatment and evaluation time. Because this is a real world study, a few 
conclusions are limited in scope, such as the lead time of ctDNA in detecting PD comparing 
to imaging modalities.   
To the best of our knowledge, this is the largest real-world study consisting of 
Chinese NSCLC patients to interrogate the value of ctDNA in monitoring treatment 
responses. Taken together, our study demonstrated the predictive and prognostic value of 
ctDNA clearance during treatment in a heterogeneous population with diverse treatment 
regiments and evaluation schedules. Furthermore, we demonstrated ctDNA analysis 
coupled with NGS is clinically meaningful in patients with advanced NSCLC by 
identifying driver mutations and resistance mechanisms to reflect dynamic molecular 
changes, thus guiding subsequent treatment.  
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Figure Legends  
Figure 1 Overview of our cohorts. A. Schematic diagram delineates the presence or 
absence of driver mutations, treatment lines, follow-up time and number of ctDNA 
performed during the study.  We screened 1,336 patients (screened cohort) to arrive at 949 
patients with driver mutations to enroll in our study (enrolled cohort). Survival analyses 
were performed on 248 patients with 2 or more follow-up tests (longitudinal cohort).  A 
total of 280 patients had 2 or more follow-up tests and 32 of them were excluded due to 
listed reasons. B. This diagram illustrates the treatment history and treatment used in our 
study of the screened cohort. The outer ring represents treatment history and inner ring 
represents treatment used in our study. Different colors refer to different treatments.  
Figure 2 Mutations identified in baseline plasma samples. A. Oncoprint of mutations 
identified at baseline of the screened cohort. Different colors denote different types of 
mutations. Top bar represents the number of mutations a patient carries; side bar represents 
the number of patients carry a certain mutation. Bottom bars provide information regarding 
histology, gender and treatment history B. Clinical characteristics (M stage, presence of 
bone metastasis, presence of liver metastasis and number of organs with lesions) associated 
with maxAF and cfDNA. T-test or Pearson correlation test was applied for continuous 
variables or binary variables, respectively. Boxplots of both variables over the 
dichotomized clinical features are shown. 
Figure 3 Correlation between baseline characteristics and overall survival. A) ctDNA 
B) mutation count. C) A signature consisting of KEAP1, KRAS and MET can predict OS. 
Patients with no mutation in the above 3 genes have a longer OS than patients with mutation 
in any one of the above 3 genes. * denotes p-value derived from cox regression model.  
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Figure 4 Predictive and prognostic value of ctDNA clearance during the course of 
treatment. A. Kaplan-Meier curves for PFS and OS in patients with a minimum of one 
time ctDNA clearance vs patients with consistent detectable ctDNA throughout the course 
of treatment. B. patients treated with MTT. C. ROC curve for changes in maxAF during 
the course of treatment. A reduction of maxAF to zero is the optimal cutoff with an AUC 
of 75%. D. Kaplan-Meier curves for PFS in patients with driver mutation clearance, all 
mutation clearance and patients with the presence of both driver and other mutations 
throughout the course of treatment. 
Figure 5 Detection of ctDNA as a function of time in patients treated with osimeritinib.  
Circulating DNA analysis schedule was depicted for each patient treated with osimertinib. 
Each line represents a patient. The length of each line corresponds to the duration of 
monitoring by ctDNA. The color dot at the beginning of each line represents the clinical 
response. Green represents no molecular progression prior to radiological progression (no 
re-elevation of ctDNA or emergence of new mutation); Yellow represents molecular 
progression proceeds radiological PD. Purple represents patients with fast progression. 
They achieved radiological PD at first evaluation. Grey dots represent patients without 
enough information to assess the sequence of radiological PD or molecular PD primary 
due to infrequent testing. X represents ctDNA clearance. Solid red squares represent 
molecular PD. Empty red squares represent no molecular PD. Solid black dots represent 
radiological PD; empty black dots represent radiological SD or PR.     
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